Daré Bioscience, Inc. (DARE) Reaches $2.65 After 3.00% Up Move; Banro (NYSEAMERICAN:BAA) Shorts Lowered By 10.41%

February 12, 2018 - By Clifton Ray

The stock of Daré Bioscience, Inc. (NASDAQ:DARE) is a huge mover today! The stock increased 42.47% or $0.79 during the last trading session, reaching $2.65. About 5.37 million shares traded or 12699.37% up from the average. Daré Bioscience, Inc. (NASDAQ:DARE) has 0.00% since February 12, 2017 and is . It has underperformed by 16.70% the S&P500.The move comes after 5 months positive chart setup for the $16.03M company. It was reported on Feb, 12 by Barchart.com. We have $2.73 PT which if reached, will make NASDAQ:DARE worth $480,750 more.

Banro Corporation (NYSEAMERICAN:BAA) had a decrease of 10.41% in short interest. BAA’s SI was 574,600 shares in February as released by FINRA. Its down 10.41% from 641,400 shares previously. With 3.86 million avg volume, 0 days are for Banro Corporation (NYSEAMERICAN:BAA)’s short sellers to cover BAA’s short positions. It closed at $0.11 lastly. It is down 74.24% since February 12, 2017 and is downtrending. It has underperformed by 90.94% the S&P500.

Banro Corporation, together with its subsidiaries, engages in the exploration, development, and production of mineral properties in the Democratic Republic of the Congo. The company has market cap of $11.39 million. It primarily explores for gold. It currently has negative earnings. The firm holds interest in 4 gold properties, including Twangiza, Namoya, Lugushwa, and Kamituga comprising 13 exploitation permits that cover an area of approximately 2,616 square kilometers in the South Kivu and Maniema provinces of the Democratic Republic of the Congo.

Daré Bioscience, Inc. develops and commercializes product for women’s reproductive health, Ovaprene. The company has market cap of $16.03 million.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>